Morgan Stanley (NYSE:MS) analyst David Lebovitz maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Tuesday, setting a price target of $194, which is approximately 21.33% above the present share price of $159.89.
Lebovitz expects Ascendis Pharma to post earnings per share (EPS) of -$1.32 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Ascendis Pharma, with an average price target of $184.
The analysts price targets range from a high of $212 to a low of $158.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.23 million and a net profit of -$73.21 million. The company’s market cap is $8.5 billion.
According to TipRanks.com, Morgan Stanley analyst David Lebovitz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.3% and a 62.86% success rate.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.